November 01, 2006 13:55 ET

DUSA Pharmaceuticals to Present at the Rodman & Renshaw 8th Annual Healthcare Conference

WILMINGTON, MASSACHUSETTS--(CCNMatthews - Nov. 1, 2006) - DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), today announced that Dr. Geoff Shulman, Chairman and CEO and Mr. Bob Doman, President and COO, will present a corporate overview at the Rodman & Renshaw 8th Annual Healthcare Conference on Wednesday, November 8, 2006 at 3:50 p.m. ET at The New York Palace Hotel in New York.

Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 14 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne and photodamage. DUSA's other dermatology products include Nicomide®, and the AVAR® line, resulting from its merger with Sirius Laboratories, Inc. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA. Please visit our website at www.dusapharma.com.

Contact Information

  • DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (416) 363-5059
    (416) 363-6602 (FAX)
    Website: www.dusapharma.com